Andolina preparation possessing anti-inflammatory, analgesic and wound-healing action

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to the pharmaceutical industry, particularly to a preparation possessing anti-inflammatory, analgesic and wound-healing action. The preparation possessing the anti-inflammatory, analgesic and wound-healing action represents a mixture of an alcoholate of lilac blossom and plantain leaves with honey and extracted juice of unpeeled pomegranate.

EFFECT: preparation possesses the pronounced anti-inflammatory, analgesic and wound-healing action.

6 ex

 

The invention relates to the creation of funds that have anti-inflammatory, analgesic and wound healing properties.

There are a large number of funds which have these pharmacological actions, alcohol, and balsamic ointment base, which contains biologically active substances of natural origin. Each of them depending on the current task has its own composition and spectrum of action.

Known medicinal herbal drug "Levallon" for the treatment of arthritis, containing the root of Valerian, a root of cinquefoil marsh, birch buds and ethyl alcohol (RF Patent 2102998 from 1995).

It is known that arthritis use leaves of lilac, arthritis and polyarthritis as a single drug, and multicomponent charges containing, for example, Labrador tea, cranberry, clover, St. John's wort, flax, nettle, mint, parsley, wheat grass, asparagus, violet and series (Minigan, z Compendium of folk medicine and alternative treatments.- M: Technikos, 1991, S. 14, 93, 103, 107-115, 170).

Famous collection of medicinal plants "Igor", used in rheumatoid arthritis, containing nettle, rosemary, St. John's wort or Valerian, Rowan, meadowsweet, series, bearberry, dill seed and flax, clover, or clover, horsetail, yarrow, rose, buds of lilac and pine, calendula, bergenia root and licorice (P the tent RF 2112534 from 1993).

Known ointment has anti-inflammatory, analgesic and wound healing action. The ointment can be used to treat sciatic nerve, osteoarthritis, rheumatoid arthritis, arthritis, sciatica, gout, myositis), diseases of the upper respiratory tract, dermatitis, burns and bruises. The ointment as the basis contains animal fat, and as active substances and plant components (RF patent 2127584 from 1999).

A disadvantage of the known dosage forms plant-based is their complexity, which leads to side effects, due to their intolerance.

The objective of the invention is to provide means anti-inflammatory, analgesic and wound healing actions with a wide therapeutic use.

The technical result consists in the fact that the tool has no toxic and side effects, has rich functionality, a more pronounced and rapid therapeutic effect with simultaneous improvement of consumer properties.

The problem is solved as follows.

The proposed tool has anti-inflammatory, analgesic and wound healing properties, which is a mixture of alcohol tinctures obtained from 1 Cup fresh flowers lilac, 1 Cup of the finely ground fresh leaves of plantain and 500 ml of 40% alcohol, 3 teaspoons of honey and 50 g of pressed pomegranate juice with rind.

Included with the tool components, taken in the optimal ratio, anti-inflammatory, wound healing and analgesic effect on the body.

The tool is prepared by thoroughly mixing alcohol tinctures, honey and pomegranate juice. 1 Cup of lilac flowers rinse under cold, running water, mix with 1 Cup of chopped fresh leaves of plantain and pour 500 ml of 40% alcohol. Infuse for two weeks, then strain and mix with 3 teaspoons of honey and 50 g of pressed juice of pomegranate peel. Store in a cool place.

Contraindications: individual intolerance.

Applied in the form of lotions and compresses in the treatment of wounds, bruises; in the form of rastrac the deposition of salts in the joints, the heel spore.

The tool was tested on volunteers.

Example 1.

Patient C. (20 years). Thermal burns to the hands 3 degrees according to the value of about 12-13 cm in diameter. To the burn superimposed ointment bandage funds 3 times a day. Inflammation has stopped on the third day, on the seventh day of treatment at the burn was formed smooth pink skin. Complete healing occurred after 20 days of treatment. On the burn scars and couplers were observed.

Example 2.

Sick So (47 years). Diagnosis: artresources to the Lenna and shoulder joints metabolic etiology; osteochondrosis of the thoracic spine. Sharp pain in knee and shoulder joints, a feeling of constriction of the thoracic vertebrae (the sensation of a foreign object). On the area of the painful places rubbing tool with light massaging movements and cover with a blanket.

The procedure is repeated 2 times during the day. Depending on the lesion, pain in these joints become dull on the second or third day, the frequency of their manifestations is greatly reduced, a sense of constriction of the thoracic vertebrae passes, disappear swelling of the soft tissues in the area of the knee and shoulder joints.

Example 3.

Patient B. (43 years). Artresources joints of the fingers, pain, impaired movement of the fingers. Completed the treatment as in example No. 2. Pain symptoms after 7 days of no treatment, restored normal operation. Fingers free, disappeared swelling and redness.

Example 4.

Patient U. (59 years). Strong debilitating pain in the lumbosacral spine radiating to the legs, the limitation of mobility. Means massaging movements rubbed in the lumbosacral spine 2-3 times a day, followed by a wrap woolen cloth. After a 2-week course of treatment is completely pain disappeared, restored mobility.

Example 5.

Patient Century (34). Hronicheskimi, complaints on susceptibility to infectious colds. Within 3 weeks, 1 time per day tool rubbed into the chest, submandibular lymph nodes, stop with the next wrap. After a week of treatment, the patient began to move away phlegm, coughing became less frequent. Upon completion of the course of treatment, all symptoms disappeared without a trace and complications. During the epidemic of influenza, the patient was not susceptible to viral diseases, disease recurrence bronchitis was no longer observed.

Example 6.

The patient, (15 Le)so Strong contusion and laceration of the left thigh, which was treated with iodine. Daily in the form of lotions were applied to the wound and rubbed into the area of injury claimed means. After 3 days of treatment disappeared redness, swelling and pain. The wounds began to heal. After a 10-day treatment - full wound healing and resorption of hematoma in the area of injury

High efficiency funds is primarily due to the wide spectrum of pharmacological actions due to the unique selection of biologically active components.

The tool can be used as prophylactic - if the patient's musculoskeletal system, diseases of the upper respiratory tract, as well as to quickly remove the pain and the inflammatory process(burns, wounds, bruises).

The tool, which has anti-inflammatory, analgesic and wound healing properties, characterized by the fact that it is a mixture of alcohol tinctures of the flowers of lilac and plantain leaves with 3 teaspoons of honey and 50 g of pressed pomegranate juice with peel, where the alcoholate obtained by soaking 1 Cup of fresh flowers lilac and 1 Cup finely ground fresh plantain leaves in 500 ml of 40% alcohol for 2 weeks, straining.



 

Same patents:

FIELD: medicine.

SUBSTANCE: present invention refers to compounds having formula III such as below, wherein: Q represents C(Y3) or N; R represents H, -R1, -R1-R2-R3, -R1-R3 or -R2-R3; R1 represents heteroaryl or heterocyclyl each of which is optionally substituted by one or more C1-6alkyls, hydroxyC1-6alkyls, oxogroups or halogenC1-6alkyls; R2 represents -C(=O), -O, -C(R2')2, -C(R2')2C(=O), -C(R2')2C(=O)NR2', C(R2')2 N(R2')C(=O), -C(=NH), -C(R2')2NR2' or -S(=O)2; each R2' independently represents H or C1-6alkyl; R3 represents H or R4; R4 represents C1-6alkyl, C1-6alkoxygroup, aminogroup, C1-6alkylaminogroup, di(C1-6alkyl)aminogroup, heterocyclyl, C1-10alkylheterocycloalkyl, heterocycloalkylC1-10alkyl each of which is optionally substituted by one or more C1-6alkyls, C1-6alkylaminogroups, di(C1-6alkyl)aminogroups, hydroxygroups, hydroxyC1-6alkyls, C1-6alkoxygroups, oxogroups or halogenC1-6alkyls; X represents CH; X' represents CH; and the rest symbols have values as specified in the patent claim. The compounds of formula III inhibit Bruton's tyrosine kinase (Btk). There are also described compositions containing the compounds of formula III, and at least one carrier, thinner or excipient, and a method for producing the compound of formula X in accordance with the following procedure.

EFFECT: compositions are effective for modulating Btk activity and treating diseases related to Btk hyperactivity, and can be used for treating inflammatory and autoimmune diseases related to disturbed B-cell proliferation, such as rheumatoid arthritis.

22 cl, 2 tbl, 260 ex

FIELD: medicine.

SUBSTANCE: method for preparing an agent possessing anti-inflammatory, diuretic and antioxidant activity, involving milling Spiraea salicifolia shoots representing a mixture of leaves, blossom and shoots, extracting them three times by gradual maceration, mixing in infusing, filtering, condensing, separating, drying in the certain environment.

EFFECT: agent shoes the pronounced anti-inflammatory, diuretic and antioxidant activity.

2 dwg, 12 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine and represents a controlled-release preparative form of diacerein administered once a day for treating or autoimmune diseases or their complications. The preparative form contains a core, an active layer, a sustained-release film layer and a delayed-release film layer, wherein the active layer is followed by the sustained-release film, and the delayed-release film layer thereafter. The sustained-release film layer contains ethyl cellulose polymer, povidone, triethylacetate and talc; the delayed-release film layer contains Eudragit polymer, triethylacetate and talc.

EFFECT: reducing the negative side action of diacerein.

18 cl, 23 ex, 33 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to microbiology, namely to using bacteria, and describes a composition containing microorganisms, a method for preparing probiotics with the anti-inflammatory action and a method for preparing an anti-inflammatory composition containing the probiotics. The composition according to the invention is characterised by the microorganism count subject to the short-time high-temperature processing at 120-140°C for 5-15 seconds.

EFFECT: invention can be used for preparing the compositions for treating or preventing the inflammatory disorders for the probiotics for dairy products.

10 cl, 7 dwg

Antiviral compounds // 2541571

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to new compounds of formula I, such as below, or its pharmaceutically acceptable salts. What is described is a method for preparing them.

,

wherein: A independently from B means phenyl,

, or ,

and B independently from A means phenyl,

, or ,

and the values Z, Y, D, L1, L2, L3, Z1, Z2 are presented in the patent claim.

EFFECT: compounds are effective for hepatitis C virus (HCV) replication inhibition.

17 cl, 3 tbl, 8 dwg, 177 ex

FIELD: medicine.

SUBSTANCE: group concerns using undecapeptide - H-Tyr-Pro-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-Gly-OH·9HCl as an analgesic agent. The group of inventions also concerns a dosage form containing the above peptide as an active substance for treating acute and chronic pain syndromes.

EFFECT: stable and prolonged analgesic effect both in the enteral, and oral route of administration.

3 cl, 2 ex, 2 dwg, 5 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention can be used in chemical-pharmaceutical industry for preparing effective tranquilising salamide preparations and analgesics. What is presented is using salicyloyl morpholine sodium salt of formula (I) as a tranquilising, nootropic and analgesic agent possessing low gastric toxicity.

EFFECT: implementing the declared application with the therapeutic index of salicyloyl morpholine of formula (I) is 3 times higher than that of mexidole, and 9,5 times higher than that of aspirin.

5 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of organic chemistry, namely to heterocyclic compound of general formula (I) or to its pharmaceutically acceptable salt, acid salt or stereoisomer, where Y: NRa and N+R1R2X-; Z: bond, -(CH2)p, -CHOH, -CH=CH-, -C≡C-, -CONH- and -CO-; Rb: C1-C8 alkyl, C2-C8 alkenyl, C6-C10 aryl, -NR5R6,: , and ; with each alkyl, alkenyl and aryl, representing Rb, possibly, contains 1-3 substituents, selected from C1-C4 alkyl, C2-C4 alkenyl, C3-C6 cycloalkyl, C1-C4 alkoxy, C6-C10 aryl, 5-, 6- and 7-membered heterocyclyl, containing 1-3 heteroatoms, selected from nitrogen, oxygen and sulphur, halogen, -OH, -NH2, -CN and -NO2; Rc: halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkinyl, C3-C10 cycloalkyl, C3-C8 cycloalkenyl, C1-C4 alkoxy, C6-C10 aryl, 5-, 6-, 7- and 8-membered monocyclic heterocyclyl, containing 1-3 heteroatoms, selected from nitrogen, oxygen and sulphur, 9- and 10-membered bicyclic heterocyclyl, containing 1-3 heteroatoms, selected from nitrogen, oxygen and sulphur; with C1-C6 alkyl, C2-C6 alkenyl C2-C6 alkinyl, C3-C10 cycloalkyl, C3-C8 cycloalkenyl, C6-C10aryl, 5-, 6-, 7-, 8-membered monocyclic heterocyclyl and 9- and 10-membered bicyclic heterocyclyl, representing Rc, possibly contain 1-5 substituents, selected from the group, consisting of C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, C3-C6 cycloalkyl, C4-C8 cycloalkenyla, halogen, -OH, -NH2, C6-C10 (A)(A')(A")(A'")aryl, (A)(A')(A")(A'")heterocyclyl, containing 1-3 heteroatom, selected from nitrogen, oxygen and sulphur, NR14R15, (CH2)pNR14R15, -CN, -NO2, oxo, -COOR14, SOR14, SO2R14, SO2NR14R15, NR15SO2R16, COR14, CONR14R15 and NR15COR16; with each (A), (A'), (A") and (A'")independently absent or representing C1-C4 alkyl, and each heterocyclyl (A)(A')(A")(A'")heterocyclyl is independently selected from the group, consisting of 5-, 6-, 7- and 8-membered monocyclic heterocyclyl, containing 1-3 heteroatoms, selected from nitrogen, oxygen and sulphur, and 9- and 10-membered bicyclico heterocyclyl, containing 1-3 heteroatoms, selected from nitrogen, oxygen and sulphur; the remaining radicals have values given in i.1;and on condition that, if Rc represents heterocyclyl, said heterocyclyl is bound directly through carbon atom of heterocyclyl ring. Invention also relates to particular compounds and to pharmaceutical composition based on formula (I) compound.

EFFECT: obtained are novel imidazopyrazine and imidazodiazepine derivatives, useful for prevention or treatment of disease or condition, severity of which is reduced by receptors to cannabinoids.

21 cl, 5 dwg, 4 tbl, 71 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to compounds of formula (I) - oxytocin receptor agonists, to their pharmaceutical compositions containing them.

EFFECT: compounds can be used for preparing a drug for treating, among others, abdominal pain, irritable bowel syndrome (IBS), autism, erectile dysfunction, female sexual dysfunction, delivery stimulation and maintenance, lactation stimulation and maintenance, post-delivery syndrome, posttraumatic stress disorder (PTSD), pain, anxiety and other conditions.

19 cl, 1 tbl, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to isoxazoline FAAH inhibitors of formula (I) or their pharmaceutically acceptable forms, wherein each of G, Ra, Rb, Rc and Rd has a value described in the present application, to pharmaceutical compositions, and methods of treating a FAAH-mediated condition.

EFFECT: developing the method of treating the FAAH-mediated condition.

32 cl, 22 tbl, 351 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine and can be used for treating an individual having a slowly healing or chronic wound. That is ensured by administering a composition containing therapeutically effective amounts of an anti-connexin43 agent, and a protein or a peptide effective for stimulating or improving the wound healing into the individual in need thereof. What is also presented is using the therapeutically effective amount of a first wound-healing compound and a second wound-healing compound, wherein the above first wound-healing compound represents the anti-connexin43 agent, while the above second wound-healing compound is specified in a group consisting of beta-adrenergic antagonists, interleukin-1 receptor antagonists, free radical scavengers, anti-inflammatory and antimicrobial agents, opioids, connexin phosphorylation agents.

EFFECT: group of inventions provides higher rate and/or quality of wound healing by means of using the above combination of the therapeutic agents when it is possible to reduce the dose and rate of administration.

46 cl, 19 dwg, 8 tbl, 11 ex

FIELD: medicine.

SUBSTANCE: invention refers to biotechnology, specifically to drug preparations of erythropoietin (EPO) for the regeneration of injured tissues, and can be used in medicine. EPO is used for producing a drug preparation for a patient's structural neogenesis. If a wound represents a burn injury, EPO is applied locally on the burn wound by a skin graft to be applied on the above wound treated by EPO. Skin diseases require the local introduction of EPO into the blood coagulate of a wound bed which is mechanically pre-treated before EPO is applied, or EPO is introduced as a part of a slow-soluble hydrogel of fibrin, polymer or alginate by the local application of the above hydrogel.

EFFECT: invention enables accelerating the granulation tissue formation accompanying the patient's structural neogenesis and ensuring the skin burn healing with no scarring.

11 ex

FIELD: medicine.

SUBSTANCE: therapeutic agent contains carboxymethyl cellulose sodium salt as a base and a combination of antiseptic, 0.01% Myramistinum and metronidazole as therapeutic ingredients. The invention provides preparing the therapeutic agent possessing the antiseptic, wound-healing and sorption action on local pyoinflammatory processes in soft tissues and mucous membranes, used in surgery, dermatology, obstetrics and gynaecology, otorhinolaryngology.

EFFECT: agent possesses the higher efficacy.

2 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: therapeutic agent contains an alloy of polyethylene oxide of molecular weight 400 and 1500 as a base and comprises a combination of antiseptic, benzalkonium chloride and metronidazole as therapeutic ingredients. The invention provides preparing the therapeutic agent possessing the antimicrobial, sorption and wound-healing action on local pyoinflammatory processes in soft tissues and mucous membranes, used in surgery, dermatology, obstetrics and gynaecology, otorhinolaryngology.

EFFECT: agent possesses the higher efficacy.

2 tbl, 3 ex

FIELD: veterinary medicine.

SUBSTANCE: preparation for treatment of infected wounds in the toe region of animals, containing dimethyl sulphoxide, methyl cellulose, additionally comprises tylosin tartrate, sulphadimine, trimethoprim in the following ratio of components, wt %: tylosin tartrate - 2-3, sulphadimine - 4-5, trimethoprim - 1-1.5, dimethyl sulphoxide - 10-15, methylcellulose - 3.0-3.5, water - the rest. The claimed method comprises applying the claimed preparation without preliminary wound cleaning. The preparation is applied to the wound with the layer thickness of 2-3 mm, without application of soft dressing. The treated animals are kept for 2-3 hours on the dry surface.

EFFECT: use of claimed group of inventions increases the efficiency of treatment.

4 cl, 7 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to surgery, and can be used for treating trophic ulcers and purulonecrotic involvements of lower extremities in diabetic patients. That requires a baseline therapy and a regional fibrinolytic therapy. Conducting the regional fibrinolytic therapy following applying a rubber bandage on the lower one-third of the shin is accompanied by administering Urokinase medac in a dose of 100 thousand units into the heel bone once a day within 5 days.

EFFECT: in the setting of reducing the total dosage of the preparation, the invention enables providing the high concentration of Urokinase medac in a pathological centre, improving microcirculation and metabolic processes in the involved tissues, accelerating the wound healing and reducing the length of hospital admission of the patients suffering from diabetic foot syndrome.

2 ex

FIELD: medicine.

SUBSTANCE: pharmacological composition contains a therapeutic agent and a pharmaceutically acceptable base. As a therapeutic agent, it contains recombinant interferon specified in a group: recombinant interferon alpha, recombinant interferon beta, recombinant interferon gamma, as well as hypromellose, boric acid as an antiseptic, anesthesin or lidocaine as local anaesthetics in the following proportions, g per 1 ml of the mixture: recombinant interferon, IU 100-10,000,000, hypromellose 0.00001-0.5, boric acid 0.00001-0.5, anesthesin or lidocaine 0.00001-0.5, a pharmaceutically acceptable base - the rest. Besides, the pharmaceutical composition contains heparin in an amount of 0.00001-0.5 g; antibiotics specified in a group of: baneocin, levomycin, tetracycline, amoxicilline in an amount of 0.00001-0.5 g. And as a pharmaceutically acceptable base, the pharmaceutical composition contains macrogol 400, or macrogol 1500, or macrogol 4000.

EFFECT: more effective treatment.

4 cl, 9 ex

FIELD: medicine.

SUBSTANCE: ulcer region is coated with macroporous hydrogel with the concentration of lightly cross-linked acrylic polymer 0.2-0.6 wt %, gel viscosity 45-85 poises at pH from 7.0 to 7.8. The wound floor is coated with a layer 2-4mm thick, and the wound edges - 1.5-3 mm, while a periulcerous region - 1-3 mm thick.

EFFECT: healing trophic ulcer 5-15 days later and no recurrence for 1-2 years as shown by patient's follow-up.

3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to new idebenone derivatives substituted by carboxylic acid with general formula I wherein R1 represents C2-C22 saccharic acid with a direct or branched chain, while two or more hydroxy groups are independently substituted by C1-C22 carboxylic acid, wherein the term 'branched' refers to one or more groups of a lower alkyl. The invention also refers to a formulation for skin treatment containing the above idebenone derivatives, a method of treating the skin changes by local applications with these idebenone derivatives, as well as to methods of synthesis thereof. When adding the idebenone derivatives according to the present invention into the formulations for local application, they possess the antioxidant action effective in treating the skin changes.

EFFECT: above idebenone derivatives have unexpectedly occurred to be effective in skin treatment, especially in relation to skin tolerance.

20 cl, 1 tbl, 5 ex

FIELD: biotechnology.

SUBSTANCE: method comprises scaling of diploid cells of line M-20 from cryobank of Institute of Poliomyelitis and Viral Encephalitis n.a. MP Chumakov of RAMS from the ampoule of the seed cell bank of 7 passage with obtaining the working cell bank of 16 passage. At that the cells of 20-33 passages, suitable for use in therapeutic and/or diagnostic purposes are produced by culturing in a nutrient medium containing 10% of human fibrinolytic active plasma (FAP), comprising platelet-derived growth factor PDGF in a concentration of from 155 to 342 pg/ml.

EFFECT: invention enables to increase proliferative activity of human fibroblast diploid cells.

2 cl, 2 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medical equipment and aims at oral cleaning. A method for providing the favourable effect for the mammalian oral cavity involves: providing a tray, contacting the above number of surfaces of the above oral cavity to the liquid, reciprocating the above liquid. The tray comprises a washing fluid chamber formed by front and back inner walls, and an inner wall of a base passing between and making a single whole with the front and back inner walls. Each of the front and back inner walls has a number of holes through which the fluid is supplied to contact the number of surfaces of the oral cavity. Contacting the number of surfaces of the oral cavity to the fluid effective for providing the favourable effect for the oral cavity. Reciprocating the above fluid about the number of surfaces of the oral cavity. The stage of reciprocating involves supplying the above liquid from a supply device to the tray and occasional pumping of the above liquid between the tray and supply device. The above fluid is simultaneously supplied to the tray and run off.

EFFECT: invention enables providing higher effectiveness of dental cleaning in the dental gaps.

12 cl, 25 ex, 1 dwg, 3 tbl

Up!